RTx is best treatment for children with ESRD. Data scarcity on DDRTx outcome in children prompted us to review our experience. This study was undertaken to evaluate patient/graft survival, function vis-a-vis SCr, rejection episodes, and mortality in DDRTx performed in 37 children between 1998 and 2011. The most common recipient diseases leading to ESRD were congenital anomalies of kidney and urinary tract (48.6%) and chronic glomerulonephritis (18.9%). Mean recipient age was 13.8 ± 3.1 yr; 67.5% (n = 25) were men. Mean donor age was 38.8 ± 18.6 yr; 48.5% (n = 18) were men. Mean dialysis duration pre-transplantation was 15.5 ± 3.5 months. All recipients received r-ATG, and triple immunosuppression. Over a mean follow-up of 3.93 ± 3.5 yr, patient and graft survival rates were 72.9% (n = 27) and 83.7% (n = 31), respectively, with a mean SCr of 1.1 mg/dL; 21.6% (n = 8) of patients had acute rejection episodes; 24.3% (n = 9) of patients had DGF. A total of 27% (n = 10) patients died, mainly owing to infections (n = 6) and cardiovascular disease (n = 3). DDRTx is a viable option for children and achieves acceptable graft function with patient/graft survival over long-term follow-up, encouraging use of this approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-3046.2012.01746.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reexamining Transplant Outcomes in Acute Kidney Injury Kidneys Through Machine Learning.
Clin Transplant
October 2024
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background: Despite many people awaiting kidney transplant, kidney allografts from acute kidney injury (AKI) donors continue to be underutilized. We aimed to cluster kidney transplant recipients of AKI kidney allografts using an unsupervised machine learning (ML) approach.
Methods: Using Organ Procurement and Transplantation Network-United Network for Organ Sharing (OPTN/UNOS) data, a consensus clustering cohort analysis was performed in 12 356 deceased donor kidney transplant recipients between 2015 and 2019 in whom donors had a terminal serum creatinine ≥1.
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France.
Lancet Diabetes Endocrinol
October 2024
Translational Research Laboratory for Diabetes, Inserm, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, University of Lille, Lille, France; Department of General and Endocrine Surgery, Inserm, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, University of Lille, Lille, France. Electronic address:
Background: Islet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to assess the effect of islet transplantation on patient-graft survival in kidney transplant recipients with type 1 diabetes.
Methods: In this retrospective cohort study, we enrolled all patients with type 1 diabetes who received a kidney graft in France during the study period, identified from the CRISTAL nationwide registry.
Effect of TIPS insertion on waitlist mortality and access to liver transplantation in Budd-Chiari syndrome.
Liver Transpl
February 2025
Division of Abdominal Transplant, Department of Surgery, Stanford University Medical Center, Stanford, California, USA.
Article Synopsis
- The study analyzed the effects of transjugular intrahepatic portosystemic shunt (TIPS) on waitlist mortality and liver transplantation access in Budd-Chiari Syndrome (BCS) patients using the UNOS database from 2002 to 2024.
- Among 815 BCS patients, those who received TIPS had lower severity scores, lesser urgent statuses, and longer waitlist times for liver transplants compared to non-TIPS patients.
- The findings revealed that while TIPS use increased over time and led to improved medical conditions at the time of transplantation, it was associated with lower access to liver transplantation and a lower risk of waitlist mortality.
Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant.
J Pharm Pract
December 2024
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Tacrolimus remains the mainstay of immunosuppression in kidney transplantation. Understanding the relationship between therapeutic tacrolimus levels and outcomes of acute rejection, patient/graft survival, and tolerability are important. The relationship between time to therapeutic tacrolimus levels and outcomes has not been well established, specifically with the use of extended release tacrolimus formulation (LCP-Tac).
View Article and Find Full Text PDFThe Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients.
Am J Nephrol
August 2024
School of Medicine, College of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
Introduction: Hepatitis B virus (HBV) infection is prevalent in Asia including Taiwan. We retrospectively evaluated the risk of HBV reactivation and clinical outcomes in HBV+ and HBV- kidney transplant recipients.
Methods: Patients who underwent kidney transplantation between January 2004 and December 2021 were reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!